By Fineline Cube Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced it has received approval from China’s National Medical Products Administration (NMPA) to initiate two Phase II/III clinical studies evaluating its first-in-class bispecific antibody-drug conjugate (ADC) iza-bren (izalontamab brengitecan) in castration-resistant prostate cancer and advanced ovarian cancer.
Clinical Trial Portfolio Expansion
| Cancer Type | Combination Regimens | Trial Phase |
|---|---|---|
| Castration-Resistant Prostate Cancer | Iza-bren + abiraterone ± olaparib Iza-bren + olaparib | Phase II/III |
| Advanced Ovarian Cancer | Iza-bren + bevacizumab ± chemotherapy Iza-bren + olaparib ± bevacizumab ± chemotherapy | Phase II/III |
Drug Profile & Innovation Status
Iza-bren (Izalontamab Brengitecan)
- Drug Class: First-in-class bispecific antibody-drug conjugate (ADC)
- Target: EGFR×HER3 dual targeting
- Development Stage: World’s only EGFR×HER3 bispecific ADC in Phase III trials
- Global Trial Presence: Over 40 clinical trials across China and the United States
- Tumor Types: Multiple solid tumors under investigation
Regulatory Recognition & Designations
NMPA Breakthrough Therapy Designations
- Total Indications: 7
- Issuing Authority: Center for Drug Evaluation (CDE)
FDA Breakthrough Therapy Designation
- Total Indications: 1
- Issuing Authority: U.S. Food and Drug Administration
Priority Review Status (China)
- Locally Advanced or Metastatic Nasopharyngeal Carcinoma
- Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
Strategic Significance
Scientific Innovation
- Novel Targeting Approach: Simultaneous EGFR and HER3 inhibition addresses key resistance mechanisms in solid tumors
- Combination Rationale: Strategic pairing with established therapies (abiraterone, olaparib, bevacizumab) leverages complementary mechanisms of action
- Broad Applicability: Platform potential across multiple tumor types with EGFR/HER3 expression
Commercial Implications
- First-Mover Advantage: Exclusive position as world’s only EGFR×HER3 bispecific ADC in late-stage development
- Regulatory Momentum: Multiple breakthrough designations accelerate development timelines and enhance commercial prospects
- Global Strategy: Simultaneous development in China and U.S. markets maximizes commercial opportunity
Market Context
- Prostate Cancer Landscape: Castration-resistant disease represents significant unmet need with limited effective options
- Ovarian Cancer Opportunity: Advanced disease requires novel approaches beyond standard platinum-based regimens
- ADC Market Growth: Antibody-drug conjugates represent one of biopharma’s fastest-growing therapeutic modalities
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical development plans, regulatory designations, and commercial potential. Actual results may differ due to clinical trial outcomes, regulatory decisions, and competitive dynamics.-Fineline Info & Tech